Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 11 - 03 tags : Therapeutics save search
Iterum Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on November 10, 2022
Published: 2022-11-03 (Crawled : 14:20) - globenewswire.com
ITRM | $1.43 -0.69% 60K
|
Health Technology
|
| O: 0.0%
H: 0.6%
C: -2.41%
report business update therapeutics financial results
Nektar Therapeutics Reports Third Quarter 2022 Financial Results
Published: 2022-11-03 (Crawled : 00:00) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: -0.84%
therapeutics financial results
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
Published: 2022-11-03 (Crawled : 22:00) - globenewswire.com
CDTX | $0.6855 -5.06% -5.32% 350K
|
Health Technology
|
| O: 1.03%
H: 2.68%
C: -3.25%
therapeutics financial update results
Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition
Published: 2022-11-03 (Crawled : 19:00) - biospace.com/
PSTX | $2.02 1.0% 0.99% 640K
|
Health Technology
|
| O: -0.52%
H: 7.63%
C: 6.84%
fviii-101 meeting therapeutics presentation therapy
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
Published: 2022-11-03 (Crawled : 14:00) - biospace.com/
GNMSF | $290.38 3.83% 220
|
Health Technology
|
| O: -2.44%
H: 5.65%
C: 5.65%
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: -2.18%
H: 8.91%
C: 8.17%
GMAB | $28.72 1.38% 1.36% 360K
|
Health Technology
|
| O: -1.73%
H: 4.51%
C: 3.15%
meeting therapeutics presentation
Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022
Published: 2022-11-03 (Crawled : 14:00) - globenewswire.com
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: -0.36%
H: 2.68%
C: -0.18%
otl-201 therapeutics presentation study
CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting
Published: 2022-11-03 (Crawled : 14:00) - globenewswire.com
CRSP M | $55.04 -1.99% -2.03% 1.8M
|
Health Technology
|
| O: -0.53%
H: 0.13%
C: -2.11%
ctx110 crispr meeting therapeutics presentation
TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
Published: 2022-11-03 (Crawled : 14:00) - globenewswire.com
TCRX | News 0 d | $6.79 -1.88% -1.91% 280K
|
Professional, Scientific, and T...
|
| O: 3.01%
H: 5.47%
C: 5.47%
meeting therapeutics presentation
Chinook Therapeutics Presents Updated Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort, Preclinical Atrasentan Research and Ongoing Clinical Trials at the American Society of Nephrology (ASN) Kidney Week 2022
Published: 2022-11-03 (Crawled : 14:00) - globenewswire.com
KDNY | $40.39 0.22% -0.17% 0
|
Health Technology
|
| O: -1.53%
H: 3.8%
C: 1.69%
ongoing nephropathy trials research preclinical kidney week therapeutics igan
4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022
Published: 2022-11-03 (Crawled : 14:00) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: -1.58%
H: 19.95%
C: 9.48%
fibrosis lung disease trial therapeutics molecular cystic fibrosis phase 1
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
Published: 2022-11-03 (Crawled : 13:20) - biospace.com/
ALDX | $3.865 -2.89% -2.98% 430K
|
Health Technology
|
| O: -0.92%
H: 3.92%
C: 2.99%
conference report therapeutics financial results
Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
BEAM | $23.9 -1.69% -1.72% 4.5M
|
Health Technology
|
| O: -2.27%
H: 6.76%
C: 3.29%
disease preclinical meeting therapeutics
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
ALLO | $3.48 0.58% 0.57% 2M
|
Health Technology
|
| O: -7.47%
H: 4.2%
C: 1.17%
meeting universal trial therapeutics presentation phase 1
Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
|
| O: 7.18%
H: 1.33%
C: -3.48%
hpn217 meeting trial therapeutics results phase 1
Regulus Therapeutics Announces Timing for Third Quarter 2022 Financial Results Webcast and Conference Call
Published: 2022-11-03 (Crawled : 13:00) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: -2.07%
H: 1.41%
C: -3.52%
conference therapeutics financial
Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022
Published: 2022-11-03 (Crawled : 13:00) - biospace.com/
LCTX | $1.15 -4.17% 0.0% 1.1M
|
Health Technology
|
| O: 0.0%
H: 5.38%
C: 1.54%
report therapeutics financial update results
Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: -0.98%
H: 1.98%
C: -0.99%
therapeutics phase 1
LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
LVTX | $2.72 -3.89% -4.04% 130K
|
|
| O: -1.31%
H: 8.85%
C: 8.41%
lava-051 meeting trial therapeutics phase 1
Fate Therapeutics to Present Clinical and Preclinical Data for iPSC Product Platform at the 2022 ASH Annual Meeting
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: -1.65%
H: 3.2%
C: -1.32%
preclinical meeting therapeutics platform
Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: -1.27%
H: 4.98%
C: 1.04%
meeting therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.